Reata Pharmaceuticals, Inc. (NASDAQ:RETA) Q3 2022 Earnings Call Transcript

And if we see data that supports the drug over the long term, reduces the risk of kidney failure and has an appropriate safety profile. We would then want to leverage that, as Warren said, with global regulatory agencies since it does address some of the fundamental questions about bardoxolone.

Operator: Thank you. And again, thank you for your participation on today’s conference call. As a reminder, an audio recording of the call will be available shortly after the call on Reata’s website at reatapharma.com in the Investors section. Thank you very much for your participation today. You may now disconnect.